Pyxis Oncology (PYXS) Enterprise Value (2021 - 2026)

Pyxis Oncology (PYXS) has reported Enterprise Value for 6 consecutive years, with $157.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 862.12% year-over-year to $157.9 million in Q2 2026; TTM through Jun 2026 was $157.9 million, a 862.12% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 115.69% from the prior year.
• Enterprise Value was $157.9 million for Q2 2026 at Pyxis Oncology, up from $5.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at $157.9 million in Q2 2026 and troughed at -$147.5 million in Q2 2022.
• A 5-year average of -$19.4 million and a median of -$33.4 million in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value jumped 7255.53% in 2024 and plunged 152.75% in 2025, its largest moves.
• Over 5 years, Enterprise Value stood at -$133.9 million in 2022, then soared by 71.07% to -$38.7 million in 2023, then grew by 13.83% to -$33.4 million in 2024, then jumped by 115.69% to $5.2 million in 2025, then jumped by 2916.05% to $157.9 million in 2026.
• The last three Enterprise Value figures came in at $157.9 million (Q2 2026), $5.2 million (Q4 2025), and $61.7 million (Q3 2025), per Business Quant data.